Track topics on Twitter Track topics that are important to you
One of the year’s most closely watched clinical studies could lead to a landmark approval of a gene therapy and throw wide open the debate over how to pay for expensive drugs. The first drips of data have emerged. Bluebird Bio (NASDAQ: BLUE) says the first three patients—of 15 total expected—have had good results from […]
Original Article: Bluebird Reports Early Results From Upgraded Gene TherapyNEXT ARTICLE
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...